Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice - Gordon, Richard; Albornoz, Eduardo A; Christie, Daniel C; Langley, Monica R; Kumar, Vinod; Mantovani, Susanna; Robertson, Avril A B; Butler, Mark S; Rowe, Dominic B; O'Neill, Luke A; Kanthasamy, Anumantha G; Schroder, Kate; et al. (Science translational medicine, 2018)
Keywords: Administration, Oral; alpha-Synuclein - toxicity; Animals; CARD Signaling Adaptor Proteins - metabolism; Disease Models, Animal; Dopaminergic Neurons - drug effects; Dopaminergic Neurons - metabolism; Dopaminergic Neurons - pathology; Extracellular Space - metabolism; Furans - administration & dosage; Furans - pharmacology; Humans; Inflammasomes - antagonists & inhibitors; Inflammasomes - metabolism; Mice; Microglia - metabolism; Nerve Degeneration - pathology; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Parkinson Disease; Protein Aggregates - drug effects; Pyroptosis; Substantia Nigra - drug effects; Substantia Nigra - pathology; Sulfonamides - administration & dosage; Sulfonamides - pharmacology